Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.62 |
| ▸ | KDR | P35968 | 5/20 | 0.62 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | AXL | P30530 | 1/20 | 0.52 |
| ▸ | MST1R | Q04912 | 2/20 | 0.51 |
| ▸ | KIT | P10721 | 1/20 | 0.50 |
| ▸ | HGF | P14210 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL371817 | 0.82 | MET (0.71) | METKDRPDGFRAPDGFRBAXL | |
| SCHEMBL3855044 | 0.81 | MET (0.55) | METKDRMST1RHGF | |
| SCHEMBL5173908 | 0.81 | MET (0.53) | METKDR | |
| SCHEMBL15090630 | 0.80 | KDR (0.55) | METKDR | |
| SCHEMBL2200943 | 0.80 | MET (0.53) | METKDRMST1RHGF | |
| SCHEMBL19689606 | 0.79 | MET (0.55) | METKDRMST1RHGF | |
| SCHEMBL2325654 | 0.79 | MET (0.52) | METKDRPDGFRA | |
| SCHEMBL15338457 | 0.78 | MET (0.60) | METKDRPDGFRAPDGFRBAXL | |
| SCHEMBL19689580 | 0.78 | MET (0.55) | METKDRMST1RHGF | |
| SCHEMBL25130187 | 0.78 | MET (0.52) | METKDRPDGFRAPDGFRBAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243339-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140057908-A1 | Method of Treating Cancer | EXELIXIS, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| EP-2621483-A1 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | Exelixis, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| US-8324245-B2 | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| WO-2012044577-A1 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | EXELIXIS, INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| US-20110229469-A1 | METHODS FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2011-09-22 | — | — | US | disclosed |
| EP-2349328-A1 | METHODS FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110105747-A1 | QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110104161-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. | 2011-05-05 | — | — | US | disclosed |
| EP-2288383-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | Amgen, Inc (US) | 2011-03-02 | — | — | EP | disclosed |
| WO-2010039248-A1 | METHODS FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009140549-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104161-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | MET, HGF, HDGF | MET 1/4885KDR 6/4885PDGFRA 28/4885 |
| US-20110229469-A1 | METHODS FOR THE TREATMENT OF CANCER | MET, HGF, EGFR | MET 1/4885KDR 23/4885PDGFRA 39/4885 |
| US-20140243339-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | MET, HGF, HDGF | MET 1/4885KDR 6/4885PDGFRA 29/4885 |
| US-20110105747-A1 | QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME | NR1H2, NR1H3, NR1H4 | MET 306/4885KDR 2963/4885PDGFRA 1768/4885 |
| US-20140057908-A1 | Method of Treating Cancer | MET, HGF, ACP3 | MET 1/4885KDR 8/4885PDGFRA 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.